www.scottishmedicines.org.uk

Statement of advice
SMC2760

bictegravir / emtricitabine / tenofovir alafenamide 30 mg / 120 mg / 15 mg film-coated tablet (Biktarvy®)

Gilead Sciences Ltd

06 December 2024

ADVICE: in the absence of a submission from the holder of the marketing authorisation

bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy®) is not recommended for use within NHSScotland.

Indication under review: treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14 kg to less than 25 kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result, we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair
Scottish Medicines Consortium

Published 13 January 2025